公开(公告)号：US5935565A

公开(公告)日：1999-08-10

申请号：US478414

申请日：1995-06-07

Applicant: Peter Besmer ,  Jochen Buck ,  Malcolm A. S. Moore ,  Karl Nocka

Inventor： Peter Besmer ,  Jochen Buck ,  Malcolm A. S. Moore ,  Karl Nocka

IPC: A61K8/00 ,  A61K8/64 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K39/395 ,  A61K48/00 ,  A61P7/00 ,  A61P7/06 ,  A61P11/00 ,  A61P25/00 ,  A61P31/12 ,  A61P35/02 ,  A61P37/08 ,  A61P43/00 ,  A61Q5/00 ,  A61Q7/00 ,  C07K14/00 ,  C07K14/475 ,  C07K14/52 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/00 ,  C07K16/22 ,  C07K19/00 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/87 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  A61K45/05 ,  A61K37/00

CPC classification number: A61K31/7072 ,  A61K38/193 ,  A61K38/202 ,  C07K14/475 ,  C07K14/52 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/22 ,  C12N15/87 ,  A61K38/00

Abstract: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

Abstract translation: 提供了包含通过申请人纯化或由申请人的重组方法与其他造血因子组合产生的c-kit配体（KL）和药学上可接受的载体的药物组合物，以及治疗患者的方法，其包括向患者施用 本发明的药物组合物。 本发明提供了使用c-kit配体（KL）和纯化的c-kit配体（KL）多肽或其可溶性片段和其他造血因子的组合疗法。 它还提供单独使用KL或联合治疗的离体使用KL方法和组合物。 还描述了突变的KL拮抗剂。 这样的拮抗剂也可以是小分子。 还描述了作为治疗剂的KL的反义核酸。 最后，描述了利用KL在生殖细胞，肥大细胞和黑素细胞中的作用的组合物和方法。

公开(公告)号：US5928931A

公开(公告)日：1999-07-27

申请号：US852481

申请日：1997-05-07

Applicant: Felix Grun ,  Jochen Buck ,  Ulrich Hammerling

Inventor： Felix Grun ,  Jochen Buck ,  Ulrich Hammerling

IPC: A61K38/00 ,  C12N1/21 ,  C12N9/88 ,  C12N15/60 ,  C12N15/63

CPC classification number: C12N9/88 ,  A61K38/00

Abstract: The present invention relates to retinol dehydratase, the enzyme which synthesizes the retro-retinoid anhydroretinol in the Spodoptera frugiperda insect cell line Sf-21, as well as the DNA molecule encoding that enzyme. The DNA molecule can be incorporated in a DNA expression system and a host for recombinant production of anhydroretinol dehydratase. The isolated retinol dehydratase protein or polypeptide of the present invention can be combined with a pharmaceutically-acceptable carrier or used alone for administration to mammals, particularly humans, for preventing cell growth and/or uncontrolled cell growth in cells which are growth dependent on retinol and/or 14 hydroxy-4, 14-retro-retinol.

Abstract translation: 本发明涉及视黄醇脱水酶，该酶是在草地夜蛾（Fododoptera frugiperda）昆虫细胞系Sf-21中合成后视黄醇脱水解蛋白的酶，以及编码该酶的DNA分子。 DNA分子可以并入DNA表达系统和用于重组生产脱氢赖氨醇脱水酶的宿主。 本发明的分离的视黄醇脱水酶蛋白或多肽可以与药学上可接受的载体组合，或者单独使用用于哺乳动物，特别是人，用于预防细胞生长和/或不依赖视黄醇生长的细胞中的不受控制的细胞生长，以及 /或14羟基-4,14-复古视黄醇。

公开(公告)号：US5786391A

公开(公告)日：1998-07-28

申请号：US371535

申请日：1995-01-11

Applicant: Lorraine J. Gudas ,  Charles Achkar ,  Jochen Buck ,  Alexander W. Langston ,  Fadila Derguini ,  Koji Nakanishi

Inventor： Lorraine J. Gudas ,  Charles Achkar ,  Jochen Buck ,  Alexander W. Langston ,  Fadila Derguini ,  Koji Nakanishi

IPC: A61K31/07 ,  A61K31/075 ,  A61K31/122 ,  A61K31/203 ,  A61K31/232 ,  A61K31/115 ,  A61K31/045 ,  A61K31/08

CPC classification number: A61K31/07 ,  A61K31/075 ,  A61K31/122 ,  A61K31/203 ,  A61K31/232

Abstract: For the first time, certain retinoids with a side chain terminal CH.sub.2 OH group or ester or ether thereof or aldehyde rather than a side chain terminal COOH group and substitution at the 4-position have been indicated to bind to nuclear receptors and to be biologically active in inducing cell differentiation of normal and tumor cells. These compounds activate gene expression through binding to nuclear receptor proteins. These compounds induce differentiation in normal and cancer cells and are useful for treating leukemias, and lymphomas, squamous cell carcinomas, deep (cystic) acne, psoriasis and photodamaged or aging skin. These compounds have stability and in vitro half-life advantages over and solubility differences from all-trans-retinoic acid and activity advantages over 13-cis retinoic acid.

Abstract translation: 具有侧链末端CH 2 OH基团或其酯或醚或具有侧链末端COOH基团的某些类维生素A和第4位的取代已被表明与核受体结合并具有生物学活性 诱导正常和肿瘤细胞的细胞分化。 这些化合物通过结合核受体蛋白激活基因表达。 这些化合物在正常和癌细胞中诱导分化，并且可用于治疗白血病，淋巴瘤，鳞状细胞癌，深（囊性）痤疮，牛皮癣和光损伤或衰老皮肤。 与13-顺式视黄酸相比，这些化合物具有超过全反式视黄酸的稳定性和体外半衰期优点和与全反式视黄酸的溶解度差异和活性优势。

公开(公告)号：US09388250B2

公开(公告)日：2016-07-12

申请号：US13202919

申请日：2010-02-23

Applicant: Jochen Buck ,  Lonny Levin ,  Jonathan Zippin

Inventor： Jochen Buck ,  Lonny Levin ,  Jonathan Zippin

IPC: A61K31/427 ,  A61K31/4184 ,  A61K31/4152 ,  A61K31/4015 ,  A61K31/496 ,  A61K31/421 ,  C07K16/40

CPC classification number: C07K16/40 ,  A61K31/427

Abstract: Soluble adenylyl cyclase (sAC) is implicated in proliferation of keratinocytes. Inhibitors of sAC are useful for the treatment and/or prevention of psoriasis and other hyperproliferative skin disorders. Assays to identify such compounds are also described.

Abstract translation: 可溶性腺苷酸环化酶（sAC）涉及角质形成细胞的增殖。 sAC的抑制剂可用于治疗和/或预防牛皮癣和其它过度增生性皮肤病。 还描述了鉴定这些化合物的分析。

公开(公告)号：US20130065246A1

公开(公告)日：2013-03-14

申请号：US13642475

申请日：2011-04-06

Applicant: Cynthia Magro ,  Jonathan Zippin ,  Lonny R. Levin ,  Jochen Buck

Inventor： Cynthia Magro ,  Jonathan Zippin ,  Lonny R. Levin ,  Jochen Buck

IPC: G01N33/574 ,  G01N33/577

CPC classification number: G01N33/5743 ,  C12Q1/527 ,  G01N33/5026 ,  G01N33/5044 ,  G01N33/5076 ,  G01N33/6893 ,  G01N2800/20 ,  G01N2800/56

Abstract: The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations.

Abstract translation: 本发明提供了一种用于诊断受试者中黑素细胞增殖的方法，包括用针对可溶性腺苷酸环化酶（sAC）的抗体染色病变黑素细胞样品，并解释与诊断黑素细胞增殖相关的sAC染色模式。 根据黑素细胞增殖的性质，复杂的sAC染色模式具有歧视性和独特性。 sAC染色模式包括点状高尔基体染色，宽粒状高尔基体染色，弥漫性细胞质染色，核仁染色，不完全粒状核染色和泛核染色中的一种或多种。 本发明的方法特别可用于确认或不肯定通过常规的样品组织学检查达成的诊断。 另外，本发明提供了用于解释黑素细胞增殖的试剂盒。

公开(公告)号：US20110305640A1

公开(公告)日：2011-12-15

申请号：US13202919

申请日：2010-02-23

Applicant: Jochen Buck ,  Lonny Levin ,  Jonathan Zippin

Inventor： Jochen Buck ,  Lonny Levin ,  Jonathan Zippin

IPC: A61K49/00 ,  C12Q1/00 ,  C12Q1/02 ,  A61K31/7088 ,  A61K31/496 ,  A61P17/00 ,  A61K31/421 ,  A61K31/4184 ,  A61K31/4025 ,  A61K31/4015 ,  A61P17/06 ,  A61K39/395 ,  A61K31/427

CPC classification number: C07K16/40 ,  A61K31/427

Abstract: Soluble adenylyl cyclase (sAC) is implicated in proliferation of keratinocytes. Inhibitors of sAC are useful for the treatment and/or prevention of psoriasis and other hyperproliferative skin disorders. Assays to identify such compounds are also described.

Abstract translation: 可溶性腺苷酸环化酶（sAC）涉及角质形成细胞的增殖。 sAC的抑制剂可用于治疗和/或预防牛皮癣和其它过度增生性皮肤病。 还描述了鉴定这些化合物的分析。